Last $4.66 HKD
Change Today 0.00 / 0.00%
Volume 1.3M
853 On Other Exchanges
Symbol
Exchange
Hong Kong
OTC US
Frankfurt
As of 4:01 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

microport scientific corp (853) Snapshot

Open
$4.64
Previous Close
$4.66
Day High
$4.70
Day Low
$4.62
52 Week High
03/6/14 - $6.30
52 Week Low
09/12/13 - $4.40
Market Cap
6.6B
Average Volume 10 Days
1.1M
EPS TTM
$0.11
Shares Outstanding
1.4B
EX-Date
06/27/14
P/E TM
33.7x
Dividend
--
Dividend Yield
--
Current Stock Chart for MICROPORT SCIENTIFIC CORP (853)

Related News

No related news articles were found.

microport scientific corp (853) Related Businessweek News

No Related Businessweek News Found

microport scientific corp (853) Details

MicroPort Scientific Corporation, a medical technology company, through its subsidiaries, develops, manufactures, and sells interventional medical devices in the People’s Republic of China. It operates through seven segments: Cardiovascular Devices, Endovascular Devices, Neurovascular Devices, Electrophysiology Devices, Orthopedic Devices, Diabetes Care and Endocrinal Management, and Surgical Management. The Cardiovascular Devices segment develops, manufactures, and sells coronary stents and related delivery systems, as well as balloon catheters and accessories. The Endovascular Devices segment offers products and therapies to treat abdominal and thoracic aortic aneurysms and peripheral vascular disease. This segment’s endovascular devices include AAA/TAA stent graft systems; Hercules balloon dilation catheters; surgical stent graft systems; and peripheral stent systems. The Neurovascular Devices segment develops, manufactures, and markets medical devices for treating the central nervous system related vascular diseases. This segment’s products include WILLIS, an intracranial stent graft system. The Electrophysiology Devices segment develops, manufactures, and markets minimally invasive medical devices for the treatment of electrophysiological diseases. The Orthopedics Devices segment develops, manufactures, and markets instruments and implants for treating orthopedic conditions. The Diabetes Care and Endocrinal Management segment develops, manufactures, monitors, and manages medical devices for the treatment of diabetes and endocrinal. The Surgical Management segment specializes in extracorporeal circulation and cardiovascular-related devices. This segment’s products consist of membrane oxygenation system, Amender PDA Occluder, and Amender ASD Occluder. The company has operations primarily in the People’s Republic of China, rest of Asia, South America, and Europe. MicroPort Scientific Corporation was founded in 1998 and is headquartered in Shanghai, China.

1,896 Employees
Last Reported Date: 04/29/14
Founded in 1998

microport scientific corp (853) Top Compensated Officers

Founder, Chairman of the Board, Chief Executi...
Total Annual Compensation: CNY4.1M
Chief Financial Officer and Member of Executi...
Total Annual Compensation: CNY934.0K
Chairman of Executive Committee and President...
Total Annual Compensation: CNY1.3M
Chief Technology Officer and Member of Execut...
Total Annual Compensation: CNY1.1M
Compensation as of Fiscal Year 2013.

microport scientific corp (853) Key Developments

MicroPort Scientific Corporation Approves Election of Weiwei Chen as Non-Executive Director and Member of Nomination Committee

MicroPort Scientific Corporation announced that at its AGM held on 30 June 2014, the shareholders approved the election of Weiwei Chen as non-executive director, with effect from 30 June 2014. In addition, the board of directors of the company announced that Ms. Weiwei Chen has been appointed as a member of nomination committee of the company with effect from 30 June 2014. She is a director of Shanghai Medical Devices (Group) Co. Ltd.

MicroPort Scientific Corporation Provides Consolidated Earnings Guidance for the First Quarter Ended March 31, 2014

MicroPort Scientific Corporation provided consolidated earnings guidance for the first quarter ended March 31, 2014. Based on the preliminary assessment of the group's latest unaudited consolidated management accounts and the information currently available to the group, is expected to record a consolidated loss for the three months ended March 31, 2014 as compared to a consolidated profit of the corresponding period in 2013. Such expected loss is mainly attributable to the one-off transitional expenses which involve integration activities in relation to the acquisition of the OrthoRecon business from Wright Medical Group Inc. and the net loss attributable to the OrthoRecon business for the three months ended March 31, 2014.

MicroPort Scientific Corporation Announces Resignation of Ganjin Chen as Non-Executive Director

MicroPort Scientific Corporation announced that Mr. Ganjin Chen has tendered his resignation as a non-executive director of the company with effect from 11 June 2014 due to other personal and business commitment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
853:HK $4.66 HKD 0.00

853 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 853.
View Industry Companies
 

Industry Analysis

853

Industry Average

Valuation 853 Industry Range
Price/Earnings 35.2x
Price/Sales 5.4x
Price/Book 2.2x
Price/Cash Flow 34.8x
TEV/Sales 3.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MICROPORT SCIENTIFIC CORP, please visit www.microport.com.cn. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.